About us

PolTREG S.A. is a biotechnology company founded in 2015. The headquarters and its laboratories are located in Gdańsk.

Learn more

The Company’s mission is to develop effective T-regulatory cell (TREG) based therapies for autoimmune diseases to improve the quality of life of patients and their families.

PolTREG’s four most advanced projects are already in the clinical stage of development in the areas of type 1 diabetes and multiple sclerosis. The portfolio also includes projects based on the next generation of genetically modified T-regulatory lymphocytes.

The PolTREG team consists of experienced managers, biotechnology specialists and scientists. The founders have over 17 years of experience in the use of T-regulatory cells in the treatment of autoimmune diseases. The Company’s Scientific Advisory Board cincludes key world-class opinion leaders.

Strategy

The Company’s strategy is to develop innovative therapies for autoimmune diseases using regulatory T lymphocytes (TREGs).

Considering the significant role these cells play in the immune system, it is sensible to expect that utilizing these cells will be crucial in treating these diseases. That is why it is important to focus on researching and developing these cells, as they hold the potential to be a platform therapy for autoimmune diseases. By doing so, we aim to become leaders in this field on a global scale. The foundation therapy platform will be created in parallel, drawing upon the progress made in the subsequent phases of developing therapies for type 1 diabetes and multiple sclerosis.

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type 1 diabetes or multiple sclerosis, followed by addressing conditions like amyotrophic lateral sclerosis, rheumatoid arthritis, inflammatory bowel disease, and other autoimmune diseases.

The Company is also developing new generation products such as CAR-TREGs and tissue-specific TREGs. The Company’s strategic objective is to partner with a prominent pharma company in order to commercialize the therapies it has developed. The Company’s funding for future development and value growth will be derived from the revenues generated through partnership agreements.

History

The development the TREG-based therapies started in 2006 at the Medical University of Gdansk and was led by Prof. Piotr Trzonkowski, Prof. Małgorzata Myśliwiec and Prof. Natalia Marek-Trzonkowska – the Company’s founders and key shareholders.

Research conducted in subsequent years demonstrated promising safety and efficacy of the developed solutions, which led to the establishment of PolTREG in 2015 as a spin-off from the Medical University of Gdansk, with the goal of developing new candidate therapies, conducting clinical trials, and commercializing the solutions. Since 2021 PolTREG is a company listed on the Warsaw Stock Exchange.

Our Facility

We are immensely proud to be constructing a modern, state-of-the art manufacturing facility, which we expect will be fully operational this year.

We believe this facility will be one of the most advanced in Europe for cell and gene therapy manufacturing. We expect to have 2100 sqm of laboratory space with 15 production lines. It will allow us to manufacture our own products at scale, and also to provide contract development and manufacturing operation (CDMO) services to third parties to GMP/cGMP standards. TREG based therapies and associated technology requires manufacturing proximity to treatment, so we consider this facility will be a useful resource for future partners selling into the European market.